Autolus Therapeutics PLC
NASDAQ:AUTL

Watchlist Manager
Autolus Therapeutics PLC Logo
Autolus Therapeutics PLC
NASDAQ:AUTL
Watchlist
Price: 2.32 USD -3.33% Market Closed
Market Cap: 617.4m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one AUTL stock under the Base Case scenario is 8.26 USD. Compared to the current market price of 2.32 USD, Autolus Therapeutics PLC is Undervalued by 72%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AUTL Relative Value
Base Case
8.26 USD
Undervaluation 72%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

68.5
P/S
P/S
Price to Sales
68.5
vs History
83
vs Industry
22
Median 3Y
100.5
Median 5Y
282.3
Industry
7.5
Forward
10.7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-5.5
Industry
24.4
Forward
-2.5
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-7.3
Industry
20.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.7
Median 5Y
-7.7
Industry
23
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
83
vs Industry
61
Median 3Y
2
Median 5Y
3.6
Industry
2.8
More Details
39.3
EV/S
EV/S
Enterprise Value to Sales
39.3
vs History
79
vs Industry
59
Median 3Y
54.8
Median 5Y
201.5
Industry
8
Forward
6.1
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-3.7
Industry
5
Forward
-1.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-3
Median 5Y
-3.5
Industry
5
Forward
-1.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-4.8
Industry
5.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-4.6
Industry
3.9
More Details
1.6
EV/IC
EV/IC
Enterprise Value to IC
1.6
vs History
79
vs Industry
68
Median 3Y
3.4
Median 5Y
5.5
Industry
5
More Details

Multiples Across Competitors

AUTL Competitors Multiples
Autolus Therapeutics PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Autolus Therapeutics PLC
NASDAQ:AUTL
617.4m USD 68.5 -3.4 -1.8 -1.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 734 413 -165 087.5 -200 468.9 -198 181.3
US
Abbvie Inc
NYSE:ABBV
344.8B USD 6 83 15.7 23.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD 374 305.7 -13 141.6 -13 213.5 -13 207.5
US
Amgen Inc
NASDAQ:AMGN
159.6B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
140.9B USD 4.9 23.6 10.3 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.8B USD 10.7 -120.1 25.5 26.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 028.2 -517.5 -563.6 -548.5
AU
CSL Ltd
ASX:CSL
127.9B AUD 5.4 30.1 18.5 23.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.5B USD 4.3 13.4 12 13.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.9B USD 22.1 -192.6 -870.6 -436.3
P/E Multiple
Earnings Growth PEG
UK
Autolus Therapeutics PLC
NASDAQ:AUTL
Average P/E: 35.4
Negative Multiple: -3.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 087.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
83
88%
0.9
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 141.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -120.1 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -517.5 N/A N/A
AU
CSL Ltd
ASX:CSL
30.1
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
7%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -192.6 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Autolus Therapeutics PLC
NASDAQ:AUTL
Average EV/EBITDA: 16.1
Negative Multiple: -1.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 468.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.6 N/A N/A
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12
11%
1.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -870.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Autolus Therapeutics PLC
NASDAQ:AUTL
Average EV/EBIT: 20.8
Negative Multiple: -1.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 181.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -548.5 N/A N/A
AU
CSL Ltd
ASX:CSL
23.1
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
11%
1.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -436.3 N/A N/A

See Also

Summary
AUTL intrinsic value, competitors valuation, and company profile.
DCF Valuation
AUTL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AUTL stock valuation using valuation multiples.
Wall Street Estimates
AUTL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AUTL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 271,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.